肿瘤药学2019，Vol.9Issue(5)：705-709,715,6.DOI:10.3969/j.issn.2095-1264.2019.05.01
一种治疗多发性骨髓瘤新药——核输出蛋白XPO-1抑制剂塞利尼索
A New Drug for Multiple Myeloma—Nuclear Export Protein XPO-1 Inhibitor Selinexor
狄潘潘 1贾淑云1
作者信息
- 1. 亳州市人民医院静配中心,安徽 亳州,236800
- 折叠
摘要
Abstract
Selinexor is a nuclear export protein XPO-1 inhibitor for the treatment of adult patients with relapsed or refractory multiple myeloma. It was developed by Karyopharm Therapeutics and approved by the U.S. Food and Drug Administration on July 3, 2019. In this article, we mainly reviewed the mechanism of drug action, preclinical research, pharmacokinetics, clinical research and adverse reactions of selinexor.关键词
塞利尼索/多发性骨髓瘤/核输出蛋白-1/临床研究/药代动力学Key words
Selinexor/Multiple myeloma/Nuclear export protein XPO-1/Clinical study/Pharmacokinetics分类
医药卫生引用本文复制引用
狄潘潘,贾淑云..一种治疗多发性骨髓瘤新药——核输出蛋白XPO-1抑制剂塞利尼索[J].肿瘤药学,2019,9(5):705-709,715,6.
